Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio Sells 4,380 Shares of Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 4,380 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Bioventus Stock Performance

NYSE:BVS opened at $9.95 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The stock has a market cap of $807.44 million, a P/E ratio of -16.31 and a beta of 0.85. The business’s 50-day moving average price is $10.34 and its two-hundred day moving average price is $10.82.

Institutional Trading of Bioventus

A number of institutional investors have recently modified their holdings of BVS. Vanguard Group Inc. boosted its holdings in shares of Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock valued at $25,852,000 after buying an additional 388,174 shares in the last quarter. Driehaus Capital Management LLC raised its position in Bioventus by 33.7% in the fourth quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock worth $11,758,000 after acquiring an additional 282,341 shares during the period. Geode Capital Management LLC boosted its stake in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after acquiring an additional 65,374 shares during the period. American Century Companies Inc. lifted its position in shares of Bioventus by 38.7% in the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock worth $9,289,000 after buying an additional 246,645 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of Bioventus by 20.9% in the fourth quarter. Nuveen Asset Management LLC now owns 782,137 shares of the company’s stock valued at $8,212,000 after acquiring an additional 135,236 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BVS. Canaccord Genuity Group boosted their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.